Grifois, S.A. - GRFS STOCK NEWS

Grifols, a leading global healthcare company, announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the SEC on April 18, 2023. This report emphasizes the company's commitment to transparency and includes financial statements compliant with International Financial Reporting Standards (IFRS), audited by KPMG. It also contains management's discussion and analysis (MD&A) detailing financial performance, key drivers of growth, and sustainability efforts. Despite receiving a deficiency letter from Nasdaq regarding an audit committee composition failure on April 13, 2023, Grifols quickly addressed the issue by appointing a compliant member, ensuring no impact on its Nasdaq listing. Investors can access the report on Grifols' website or request a hard copy.

Selagine, Inc., a spin-out from the University of Illinois at Chicago, has partnered with Grifols (NASDAQ: GRFS) to develop immunoglobulin eye drops aimed at treating dry eye disease. This biologic eyedrop contains functional antibodies from human plasma, showing promising results in a pilot trial, significantly reducing dry eye symptoms without adverse effects compared to placebo. The agreement involves an upfront payment, annual fees, and joint funding for FDA approval. The dry eye market is forecasted to exceed $6.5 billion by 2027, highlighting the potential financial impact of this collaboration.

Grifols has announced a leadership change, with Victor Grifols Roura retiring as Chairperson and being named Chairperson of Honor after a 50-year tenure. Steven F. Mayer, an experienced private equity executive and Grifols board member since 2011, is appointed as Executive Chairperson. This transition aims to enhance operational excellence and accelerate the company's strategic objectives, particularly focusing on deleveraging the balance sheet and improving cash flow. Mayer's extensive industry knowledge positions him well to lead Grifols forward as it continues to recover from the challenges posed by the pandemic.

Grifols, S.A. filed its 2021 Annual Report on Form 20-F with the SEC on April 29, 2022. The report includes audited financial statements for the fiscal year ending December 31, 2021, reflecting Grifols' commitment to transparency for its shareholders. The Form 20-F is accessible on Grifols' website and the SEC's site. Shareholders can request a hard copy of the report free of charge. Grifols has an economic impact of €7,700 million and is a major player in the plasma industry with over 23,000 employees in 30+ countries.

Grifols has successfully acquired 100% of Tiancheng Pharmaceutical Holdings AG, providing a 96.20% voting rights control over Biotest AG. The transaction, valued at approximately EUR 1,600 million, enhances Grifols' capabilities in plasma therapies, expanding its network to 87 plasma centers. This strategic acquisition aims to accelerate growth, boost revenues, and improve profitability starting in 2024 through new product launches. Regulatory approvals were secured from authorities in Turkey, Germany, and Spain, underlining the transaction's significance.

Grifols (GRFS) has partnered with Feeding America to combat hunger in the U.S. through its Box Out Hunger initiative. In March, Grifols aims to collect over 1 million pounds of nonperishable food by collaborating with local businesses and community organizations. Last year, the program gathered 800,000 pounds. Employees and donors can also contribute monetarily, with the J.A. Grifols Foundation matching donations. This marks the first collaboration with Feeding America, enhancing Grifols' commitment to social responsibility while supporting the urgent need for plasma donations amidst the COVID-19 pandemic.

Grifols (NASDAQ: GRFS) announced a collaboration with Endpoint Health to develop and commercialize Antithrombin III (AT-III) therapy targeting Sepsis. Grifols will be the exclusive supplier of AT-III, contributing $25 million to support clinical development. An Investigational New Drug (IND) application will be submitted for a Phase II trial later this year. Endpoint Health will utilize its AI technology to identify patients likely to benefit from AT-III. The collaboration aims to improve patient outcomes and strengthen Grifols' plasma economics.

Grifols, a leader in plasma-derived medicines, announced its PharmacyKeeper Verification software has been named the No. 1 Category Leader in IV Workflow Management by KLAS Research for the sixth consecutive year. This accolade underscores Grifols' commitment to enhancing patient care through technology. PharmacyKeeper is part of Grifols' IV compounding solutions, which aim to reduce medication errors, while the Best in KLAS report emphasizes user feedback to recognize top healthcare technology vendors.

Grifols has acquired its first plasma donation center in Canada, purchasing Prometic Plasma Resources Inc's Winnipeg site from Kedrion for USD 4 million. This acquisition supports Grifols’ strategy to enhance the availability of lifesaving plasma medicines in Canada, complementing its existing production capabilities in the country. With an annual capacity of 1.5 million liters at its plasma fractionation plant, Grifols aims to leverage its extensive experience in Canadian plasma. The company remains committed to ensuring the quality and safety standards of plasma usage for patients.